Literature DB >> 11884649

Estimating the prevalence of agitation in community-dwelling persons with Alzheimer's disease.

Rochelle E Tractenberg1, Myron F Weiner, Leon J Thal.   

Abstract

To estimate the prevalence of, and develop norms for, significant agitation in community-dwelling persons with Alzheimer's disease (AD), the authors applied three different criteria to persons with AD (n=235) and normal elderly control subjects (NEC; n=64). The criteria were used to identify the minimum total score on the Cohen-Mansfield Agitation Inventory (CMAI) that represents significant or "excessive" agitation and to estimate its prevalence. The "ultraliberal" criterion resulted in 99.1% of persons with AD and 56.6% of NEC being classified as "excessively" disturbed. The "liberal" and "conservative" criteria classified 66.7% and 68.2% of persons with AD, and no NEC, as "excessively" disturbed. The authors conclude that the best estimate of prevalence of excessive agitation in this population is 67.5%, and that individuals with CMAI scores of 0 to 14 probably should not be considered to have excessive agitation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884649     DOI: 10.1176/jnp.14.1.11

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  11 in total

Review 1.  Risperidone for the treatment of neuropsychiatric features in dementia.

Authors:  Alistair Burns; Peter P De Deyn
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  A meta-analysis of mood stabilizers for Alzheimer's disease.

Authors:  Haibing Xiao; Ying Su; Xu Cao; Shenggang Sun; Zhihou Liang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

3.  Cause for Concern: Behavioral and Psychological Symptoms of Dementia in Delaware's Long-Term Care Facilities.

Authors:  Steven J Banko; Cecelia Harrison; Jennifer Rittereiser; Claudine Jurkovitz; James M Ellison
Journal:  Del Med J       Date:  2021 Mar-Apr

4.  The application of an information support robot to reduce agitation in an older adult with Alzheimer's disease living alone in a community dwelling: a case study.

Authors:  Jumpei Mizuno; Ken Sadohara; Misato Nihei; Shinichi Onaka; Yuko Nishiura; Takenobu Inoue
Journal:  Hong Kong J Occup Ther       Date:  2021-04-18       Impact factor: 0.917

5.  Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease.

Authors:  Paula T Trzepacz; Peng Yu; Phani K Bhamidipati; Brian Willis; Tammy Forrester; Linda Tabas; Adam J Schwarz; Andrew J Saykin
Journal:  Alzheimers Dement       Date:  2012-12-17       Impact factor: 21.566

6.  Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease.

Authors:  Rochelle E Tractenberg; Myron F Weiner; Marian B Patterson; Linda Teri; Leon J Thal
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-06       Impact factor: 2.680

7.  [The Determination of Agitation Behaviors among the Elderly People Receiving Long-Term Institutional Care and the Influencing Factors].

Authors:  Serap Bayram; Esra Usta; Özlem Altınbaş-Akkaş; Tuğçe Şık
Journal:  Florence Nightingale Hemsire Derg       Date:  2019-06-01

8.  The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study.

Authors:  Sibel Cakir; Isin Baral Kulaksizoglu
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

9.  Serum Copper, Zinc, and Iron Levels in Patients with Alzheimer's Disease: A Meta-Analysis of Case-Control Studies.

Authors:  Dan-Dan Li; Wei Zhang; Zhan-You Wang; Pu Zhao
Journal:  Front Aging Neurosci       Date:  2017-09-15       Impact factor: 5.750

10.  Institutionalization risk and costs associated with agitation in Alzheimer's disease.

Authors:  Martin Cloutier; Marjolaine Gauthier-Loiselle; Patrick Gagnon-Sanschagrin; Annie Guerin; Ann Hartry; Ross A Baker; Ruth Duffy; Keva Gwin; Myrlene Sanon Aigbogun
Journal:  Alzheimers Dement (N Y)       Date:  2019-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.